Idiopathic pulmonary fibrosis (IPF) is an aggressive disease in which normal lung parenchyma
is replaced by a stiff dysfunctional scar rich in activated fibroblasts and collagen-I. We …

Large cell carcinoma (LCC) is a rare and aggressive lung cancer subtype with poor prognosis
and no targeted therapies. Tumor-associated fibroblasts (TAFs) derived from LCC tumors …

The contribution of epithelial-to-mesenchymal transition (EMT) to the profibrotic stiff
microenvironment and myofibroblast accumulation in pulmonary fibrosis remains unclear. We …

Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an important regulator of extracellular matrix
turnover that has been traditionally regarded as a potential tumor suppressor owing to its …

This study implicates the selective epigenetic repression of SMAD3 in SCC-TAFs in the
clinical failure of nintedanib in SCC and supports that patients with ADC may benefit from …

Myofibroblasts are a population of highly contractile fibroblasts that express and require the
activity of the transcription factor Snail1. Cancer‐associated fibroblasts (CAFs) correlate with …

The fibrotic tumor microenvironment is a pivotal therapeutic target. Nintedanib, a clinically
approved multikinase antifibrotic inhibitor, is effective against lung adenocarcinoma (ADC) but …

The 16th ERS Lung Science Conference (LSC) took place on March 8–11, 2018, in Estoril,
Portugal, with around 200 delegates from all over the world. This year’s topic was “Cell-…

Background: Lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC) are the
most common histologic subtypes in lung cancer. Intriguingly, ADC and SCC exhibit distinct …

Adenocarcinoma (ADC) and Squamous Cell Carcinoma (SCC) are the most frequent
histologic subtypes of lung cancer, and both are rich in activated/myofibroblast-like tumor-…